[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857-209-0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 63, "title": "CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2020, "totalPay": 612000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 57, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2020, "totalPay": 589000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Piekos", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  DiVecchia", "title": "Senior Vice President of Operations & Human Resources", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan C. Filoon", "title": "General Counsel, Secretary & Compliance Officer", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thian  Kheoh Ph.D.", "title": "Senior Vice President of Biometrics", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1719619200, "compensationAsOfEpochDate": 1609372800, "maxAge": 86400, "priceHint": 4, "previousClose": 6.89, "open": 4.2, "dayLow": 4.1, "dayHigh": 4.75, "regularMarketPreviousClose": 6.89, "regularMarketOpen": 4.2, "regularMarketDayLow": 4.1, "regularMarketDayHigh": 4.75, "forwardPE": -1.3431373, "volume": 407069, "regularMarketVolume": 407069, "averageVolume": 51868, "averageVolume10days": 68400, "averageDailyVolume10Day": 68400, "marketCap": 42210936, "fiftyTwoWeekLow": 2.96, "fiftyTwoWeekHigh": 11.45, "fiftyDayAverage": 8.4086, "twoHundredDayAverage": 6.78795, "currency": "USD", "enterpriseValue": 36970460, "floatShares": 5425847, "sharesOutstanding": 10270300, "sharesShort": 75781, "sharesShortPriorMonth": 90442, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0074, "heldPercentInsiders": 0.29513, "heldPercentInstitutions": 0.04042, "shortRatio": 1.92, "shortPercentOfFloat": 0.0094, "impliedSharesOutstanding": 10270300, "bookValue": 0.477, "priceToBook": 8.616352, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -38993000, "trailingEps": -3.82, "forwardEps": -3.06, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -0.977, "52WeekChange": -0.55995715, "SandP52WeekChange": 0.22553468, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ELTX", "underlyingSymbol": "ELTX", "shortName": "Elicio Therapeutics, Inc.", "longName": "Elicio Therapeutics, Inc.", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f5a7063e-a200-3645-afdf-a5955dd38a4c", "messageBoardId": "finmb_214936128", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.11, "targetHighPrice": 10.0, "targetLowPrice": 10.0, "targetMeanPrice": 10.0, "targetMedianPrice": 10.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 11853000, "totalCashPerShare": 1.156, "ebitda": -37827000, "totalDebt": 6672000, "quickRatio": 1.992, "currentRatio": 2.374, "debtToEquity": 137.002, "returnOnAssets": -0.95538, "returnOnEquity": -12.88174, "freeCashflow": -20728088, "operatingCashflow": -36677000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-30"}]